Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study

Ki vehet részt

• Age ≥ 12 years at the time of signing informed consent
• Clinical diagnosis of non-segmental vitiligo with facial involvement, and total body surface area (BSA) depigmentation ≤ 10%
• Diagnosed with progressive/active vitiligo meeting at least one of the following: Vitiligo Disease Activity (VIDA) score ≥ 3; Clinical signs including trichrome vitiligo, confetti-like depigmentation, or Koebner phenomenon; The extent of lesions under Wood's lamp is larger than that visible to the naked eye
• Agrees to have no pregnancy plans and uses effective contraception during the study and up to 4 weeks after the last dose
• Voluntarily signs the informed consent form and agrees to regular follow-up visits

Ki nem vehet részt

• Contraindications to systemic corticosteroid use
• Concurrent participation in other clinical studies
• Co-existing skin depigmentation disorders affecting efficacy evaluation (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, chemical leukoderma, tinea versicolor)
• Known hypersensitivity or allergy to the study medications or excipients
• Known end-stage renal disease (ESRD) or currently undergoing renal replacement therapy (e.g., dialysis)
• Any other condition which, in the investigator's judgment, makes the patient unsuitable for the study
• Diagnosis of other clinical forms of vitiligo (e.g., segmental vitiligo)
• Clinically diagnosed with stable vitiligo
• Leukoderma lesions with more than 1/3 white hair, or lesions accompanied by white hair where the investigator assesses the probability of benefit from participating is low based on clinical experience